Treatment and Suppression of Hairy Leukoplakia in ARC Patients With Oral Acyclovir (ACV)
To evaluate the efficacy of oral acyclovir for the treatment and suppression of Epstein-Barr virus (EBV) related hairy leukoplakia (HL). To determine the long-term safety of acyclovir in the AIDS-related complex (ARC) patient with HL. To monitor the progression of HIV disease in the HL patient and compare to existing historical control data.
|Study Design:||Primary Purpose: Treatment|
|Official Title:||Treatment and Suppression of Hairy Leukoplakia in ARC Patients With Oral Acyclovir (ACV)|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00002026
|United States, California|
|Univ of Southern California / LA County USC Med Ctr|
|Los Angeles, California, United States, 900331079|